Organs at risk radiation dose constraints.

{"article_title":"Organs at risk radiation dose constraints.","author":"No\u00ebl G, Antoni D","journal_title":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique","issn":"1769-6658","isbn":"","publication_date":"2022-02-01","volume":"26","issue":"1-Feb","first_page":"59","page_count":"","accession_number":"34953713","doi":"10.1016\/j.canrad.2021.11.001","publisher":"Elsevier","doctype":"Journal Article","subjects":"France; Organs at Risk radiation effects; Radiation Injuries prevention & control; Radiosurgery methods; Radiotherapy, Intensity-Modulated methods; Dose Fractionation, Radiation; France; Humans; Organ Specificity radiation effects; Radiation Dosage; Radiation Oncology; Re-Irradiation methods; Societies, Medical","interest_area":["Oncology"," Radiology"],"abstract":"Dose constraints are essential for performing dosimetry, especially for intensity modulation and for radiotherapy under stereotaxic conditions. We present the update of the recommendations of the French society of oncological radiotherapy for the use of these doses in classical current practice but also for reirradiation. Copyright \u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=34953713","isPdfLink":false,"isSAML":false,"an":"34953713","number_other":"","type_pub":"","issn_electronic":"1769-6658","languages":"English","language":"eng","date_entry":"Date Created: 20211226 Date Completed: 20220217 Latest Revision: 20220217","date_update":"20240104","titleSource":"Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2022 Feb-Apr; Vol. 26 (1-2), pp. 59-75. Date of Electronic Publication: 2021 Dec 23.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2022-02-01","description":"Dose constraints are essential for performing dosimetry, especially for intensity modulation and for radiotherapy under stereotaxic conditions. We present the update of the recommendations of the French society of oncological radiotherapy for the use of these doses in classical current practice but also for reirradiation.<br \/> (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=34953713&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"No\u00ebl G, Antoni D"}